Banxia-Xiexin-Decoction-based sequential therapy for Helicobacter pylori infection eradication: a real-world study

Not Applicable

• Conditions: Hp infection

• Registration Number: ITMCTR2000003473
• Lead Sponsor: Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) Meet the diagnostic criteria;
(2) Aged 18-70 years;
(3) Actively cooperated with the treatment and willing to accept the follow-up visit as the observation objects;
(4) Did not take any drugs related to the treatment effect of this study within 4 weeks before the start of the observation.

Exclusion Criteria

(1) Patients who had HP eradication treatment within 6 months;
(2) patients with gastrointestinal ulcer indicated by endoscopy;
(3) patients with liver and kidney dysfunction, severe cardiovascular and cerebrovascular diseases, and malignant tumor diseases;
(4) those who were definitely diagnosed with mental disorders, speech and behavior disorders;
(5) pregnant or lactating women;
(6) patients with drug allergy history;
(7) patients with liver and kidney dysfunction and severe cardiovascular and cerebrovascular diseases and malignant tumor diseases Participants or participants in other drug trials in the past 3 months.

Study & Design

• Study Type: Observational study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
C-13 breath test;

Secondary Outcome Measures

Name	Time	Method
Symptom score;